Notice of AGM & Posting Annual Report and Accounts

RNS Number : 6200C

N4 Pharma PLC

24 February 2022

 

24 February 2022

N4 Pharma Plc

("N4 Pharma" or the "Company")

Notice of Annual General Meeting

and

Posting of Annual Report and Accounts

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, announces that the Company's audited accounts for the year ended 31 December 2021, together with the notice of Annual General Meeting ("AGM"), are now available on the Company's website  www.n4pharma.com   and will be posted to shareholders today.

The AGM will be held at 11.00am on 24 March 2022 at Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street, London, EC3V 0HR.

Enquiries:

N4 Pharma Plc Nigel Theobald, CEO Luke Cairns, Executive Director	Via IFC Advisory
SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Rob Rees (Corporate Broking)	Tel: + 44 (0)20 3470 0470
Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker	Tel: [phone]
IFC Advisory Limited Financial PR Graham Herring Zach Cohen	Tel: [phone]

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive up front payments, milestone payments and ultimately royalty payments once products reach the market.

 

END

 

 

MSCSEUFMDEESEIE